Kornimate/medical-research-clean huggingface dataset:
aml electronic decision aid

Conditions: Acute Myeloid Leukemia

Summary: the purpose of this study is to test the feasibility and preliminary efficacy of a novel electronic decision aid to improve aml patients' understanding of their illness, prognosis, and treatment options.

the purpose of this study is to test the feasibility and preliminary efficacy of a novel electronic decision aid to improve aml patients' understanding of their illness, prognosis, and treatment options. the objective of our program of research is to ultimately improve understanding about what patients with acute myeloid leukemia (aml) know and understand about their disease, as well as what kind of information aml patients want or need to further inform them about the treatment decisions they face. the aml decision aid tool consists of ten video modules, approximately 3 minutes each, containing content regarding key areas such as an explanation of what aml is, treatment choices, and things to consider when determining a treatment path. recruited subjects will complete a series of surveys, both before viewing of the videos and after

Eligibility criteria:
inclusion criteria: * at least age 18 * capacity to give consent * diagnosis of acute myeloid leukemia (aml) * fluent in english * receiving care at duke, and fits into one of the following scenarios: * has not yet made a treatment decision (in the dci clinics or on the inpatient wards), * have recently made a decision (in the last 6 weeks), and are admitted for chemotherapy on 9100 or in the oncology treatment center to receive outpatient therapy, * or, during remission, while receiving consolidation chemotherapy in the hospital exclusion criteria: * patients too sick to participate per clinician discretion
treatment of facial burns with flammacerium compared to flammazine and the impact of facial burns on psychosocial wellbeing

Conditions: Burns

Summary: the face is involved in 40-50% of patients with burns admitted to the dutch burn centres. scarring of the face as a consequence of burns will often have a detrimental effect on function and aesthetics, and may cause negative effects on psychosocial wellbeing. what the best treatment is for facial burns, minimising scarring, is unclear. besides that, there is little empirical evidence regarding the impact of facial scarring on psychosocial wellbeing. in clinical practice good results are felt to be achieved by treatment of facial burns with flammacerium. to substantiate the perceived advantages of flammacerium, its efficacy is compared to flammazine, a current alternative of care. the efficacy of treatment will be assessed in a prospective randomised multicentre clinical trial. efficacy will be analysed in terms of number of patients requiring surgery and functional and aesthetic outcome. apart from medical outcome, this study offers the opportunity to study psychosocial problems associated with facial defects. it is still an unresolved question whether facial scarring causes more or different psychosocial problems. therefore, self-esteem and quality of life will be examined over time, in relation to depression, posttraumatic stress symptoms and other factors, such as coping style and social support. by evaluating the efficacy of different treatment strategies, we aim to optimise the standard of care of facial burns. furthermore, this study wants to shed more light on the psychosocial impact of facial injury. with these results psychosocial professionals will be able to focus on persons at risk and to be better able to meet a patient's personal needs.


Eligibility criteria:
inclusion criteria: * patients of 18 years of age or older, competent or temporarily incompetent, who are admitted to one of the three dedicated dutch burn centres with burn injuries involving the face exclusion criteria: * patients not seen within 24 hours postburn * patients with mental or cognitive deficits that may interfere with providing informed consent * patients with poor dutch proficiency * patients with chemical burns

Keywords: facial burns cerium flammazine quality of life randomised clinical trial
matrilysin expression in different stages of colorectal tumors

Conditions: Colorectal Cancer Stage 0; Colorectal Cancer Stage I; Colorectal Cancer Stage II; Colorectal Cancer Stage III; Colorectal Cancer Stage IV

Summary: matrix metalloproteinases (mmps) have been shown to be involved in cancer biology. significant expression of mmp-7 (matrilysin) in colorectal cancer is mainly associated with metastatic disease even though it is expressed in most tumor states. our purpose is to analyse mmp-7 in bowel and lymph nodes of different tumor stages and to evaluate its expression as a potential biomarker of cancer disease in patients surgically treated for benign and malignant colorectal tumors. tumoral tissue, lymph nodes and serum samples from recruited patients plus serum samples from healthy volunteers are analysed for matrilysin expression by histology, immunohistochemistry, elisa and western blotting. if matrilysin increases with increasing dysplasia and cancer disease stage in tumor tissue as well as in the regional lymph nodes it might be used as a complement in investigating suspected locally advanced cancer.


Eligibility criteria:
inclusion criteria: * benign colonic neoplasm not suitable for endoscopic treatment, * malignant colonic neoplasm with indication to primary surgical treatment exclusion criteria: * neo-adjuvant radiotherapy, * chemo-radiotherapy, * language problems and withdrawal of consent

Keywords: matrilysin mmp-7 colorectal cancer adenoma lymph nodes
cognitive impairment and neuropsychiatric manifestations of neurobrucellosis

Conditions: Brucellosis

Summary: brucellosis is a common zoonotic infection in many parts of the world including the mediterranean and middle eastern countries. neurobrucellosis may develop at any stage of disease and may have widely variable manifestations, including encephalitis, meningoencephalitis, radiculitis, myelitis, peripheral and cranial neuropathies, subarachnoid hemorrhage, and psychiatric manifestations.

brucellosis is a common zoonotic infection in many parts of the world including the mediterranean and middle eastern countries. neurobrucellosis may develop at any stage of disease and may have widely variable manifestations, including encephalitis, meningoencephalitis, radiculitis, myelitis, peripheral and cranial neuropathies, subarachnoid hemorrhage, and psychiatric manifestations. the aimed is to shed light to the obscure areas of diagnosis in neurobrucellosis and have detailed general and neurologic features

Eligibility criteria:
inclusion criteria: * patients \>18 years of age with laboratory-confirmed brucellosis exclusion criteria: * previous neuropsychiatric disease

Keywords: brucellosis, neuropsychiatric manifestations, cognition
acamprosate treatment: mechanisms of action

Conditions: Alcoholism

Summary: this study will examine whether pretreatment with two doses of acamprosate for seven days prior to abstinence lessens the intensity of acute withdrawal from alcohol compared with a placebo. subjects will be randomly assigned to receive either one of two doses of acamprosate or placebo for seven days. this will be followed by a four- day inpatient period when withdrawal will be monitored. additional drinking information will be obtained at a three month followup interview.


Eligibility criteria:
inclusion criteria: * meets criteria for alcohol abuse or dependence. * able to read english at 6th grade level or higher and to complete study evaluations. * average weekly alcohol consumption of standard drinks of at least 25 drinks for men and 20 drinks for women. * no more than 3 days abstinence/week. exclusion criteria: * current abuse or dependence on other substances, other than nicotine and marijuana. * positive test results for opiates, cocaine, benzodiazepines and barbiturates. * regular use of psychoactive drugs including anxiolytics and antidepressants. * psychiatrically disabled. * hepatocellular disease or a history of cirrhosis. * medical conditions that would prevent the consumption of alcohol, increase the risk of complicated alcohol withdrawal, or prevent the use of acamprosate such as a history of neurological trauma or disease, seizures, delirium, or hallucinations, hepatic, cardiovascular, metabolic, endocrine, gastrointestinal, or kidney disease. * individuals who have had any significant physical illnesses during the two weeks prior to receiving study medication or during the medication treatment period prior to the withdrawal study. * medically detoxified from alcohol more than once within the past five years. * alcohol withdrawal symptoms requiring management with benzodiazepines. * females who are pregnant, nursing or not using a reliable method of birth control. * individuals who are seeking alcohol treatment or have been in alcohol treatment within the past six months. * individuals who report disliking spirits and have taken investigational drug or naltrexone within 4 weeks immediately preceding admission to study. * individuals who report any daily drug use during the thirty days prior to randomization for the following: anxiolytics, beta blockers, central nervous system stimulants, hypnotics, non-therapeutic doses of neuroleptics and antidepressants, drugs with psychotropic activity or drugs which cause excessive sedation. * subjects who have donated blood within the past six weeks.
validity of the french version of the quality of life questionnaire comq12-fr

Conditions: Chronic Otitis Media

Summary: the world health organization estimates that chronic otitis media could reach between 65 and 350 million people worldwide and thus be an important cause of medical consultation and prescription drugs. the medical care of chronic otitis is difficult, despite several medical and surgical treatment options. moreover this pathology is gladly recurrent. the completion of a standardized questionnaire to track symptoms objectively over time is fundamental to verify the efficacy of specific treatments and to compare treatments. the quality of life measurement questionnaire related to chronic otitis media (comq-12) is a new questionnaire, validated in english, to assist the physician in evaluating chronic otitis media. the objective of this study is to translate and validate the test in french in children.

the world health organization estimates that chronic otitis media could reach between 65 and 350 million people worldwide and thus be an important cause of medical consultation and prescription drugs. the medical care of chronic otitis is difficult, despite several medical and surgical treatment options. moreover this pathology is often recurrent. the completion of a standardized questionnaire to track symptoms objectively over time is fundamental to verify the efficacy of specific treatments and to compare treatments. the quality of life measurement questionnaire related to chronic otitis media (comq-12) is a new questionnaire, validated in english, to assist the physician in evaluating chronic otitis media. the original version of the comq12 questionnaire, in english, was developed by phillips et al.. the construction of this questionnaire was based on three other questionnaires : the chronic ear survey (ces), the chronic otitis media outcome-15 (comot-15), and the chronic otitis media-5 (com-5). the initial validation of the english version of phillips et al. was evaluated with an alpha value of cronbach to 0.889, which shows high internal consistency and would allow its use in several reputed international centers of otology. the objective of this study is to translate and validate the test in french in children.

Eligibility criteria:
inclusion criteria: * minors aged 7 to 15 years (inclusive) * patients with chronic otitis media, united or bilateral * controls: subjects without chronic otitis media or any other pathology of the ear at the time of inclusion or in background * holders of parental authority not opposed to participation in the study exclusion criteria: - non-comprehension of french

Keywords: chronic otitis media in children standardized quality of life measurement questionnaire
measuring real time decision-making about ultraviolet radiation (uvr) protection

Conditions: Melanoma

Summary: the purpose of this study is to understand how people make decisions about sun protection. this study is important in helping to protect against sun exposure, since it is a main risk factor for melanoma. the investigators would like to understand the decisions people make about sun protection so that they can improve their ability to help individuals who may be at risk for melanoma.


Eligibility criteria:
inclusion criteria: * a first-degree biological relative (a child, sibling or parent) as per self report of an mskcc follow-up surgical patient diagnosed with melanoma as per pathology report or clinician's judgment; * english-fluent; the surveys were designed and validated in english and are not currently available in other languages. translation of questionnaires into other languages would require reestablishing the reliability and validity of these measures. therefore, participants must be able to communicate in english to complete the surveys. * 18 years of age or older; * for phase i only: fdrs who live within a 50 mile radius of mskcc to make it feasible for ms. shuk to be able to arrive at each person's home for the in-home interview without the cost being prohibitive; * for phase i only: can recall a period when s/he was out in the sun for at least one hour on a sunny day this past summer 2009. * for phase i only: can recall a separate period when s/he was out in the sun for at least one hour on a sunny day this past summer 2009, but s/he was in a different location from the period referenced above. * for phase ii only: fdrs who self-report at least 1 consecutive hour in the morning (dawn to 12:30pm) and 1 consecutive hour in the afternoon (12:30-5pm) of daily (weekend and weekday) outdoor activities on the screening questionnaire exclusion criteria: * first-degree relatives of melanoma patients who report never using uvr protection; * patient's who provide consent for phase i will not be eligible for phase ii. * any first-degree relative of a melanoma patient who already has a first-degree relative who consented to the study; * unable to provide informed consent.

Keywords: skin sunscreen uvr protection 09-137
a study to evaluate the efficacy and safety of buma supreme drug eluting stent(des)

Conditions: Coronary Artery Disease

Summary: pioneer-ii opc trial is a prospective, multicenter, single-arm registry trial. 1000 subjects from approximately 40 interventional cardiology centers will be enrolled to evaluate the target lesion failure(tlf) as the primary endpoint at 1 year. and all the subjects will be followed up to 5 years to attain the data of the secondary endpoints.

realizing even more uniform and complete endothelial coverage, buma supreme™ biodegradable drug coating coronary stent system comprises a new generation of biodegradable drug eluting stent under development by sino medical science(sinomed). buma supreme™ reconfigures buma™ des utilizing a high caliber cobalt chromium platform coated with rapidly degrading plga scaffold.

Eligibility criteria:
inclusion criteria: 1. age 18-75, male or non-pregnant female 2. evidence of non-symptomatic ischemia, stable or non-stable angina pectoris or past mi 3. target lesion is primary and de-novo coronary artery disease 4. the target lesion length ≤ 60 mm, diameter 2.25mm-5.0mm (visually estimated) 5. lesion diameter stenosis ≥70% (visually estimated) 6. for each target lesion, same stent implantation only 7. acceptable candidate for coronary artery bypass grafting(cabg) 8. understand the study purpose, willing to participate and sign the letter of consent, agrees to the follow-up visits including a 9 month angiographic follow-up exclusion criteria: 1. acute mi within 1 week 2. chronic total occlusion(timi 0), left main lesion, intervention-required three-vessel lesions, branch vessel diameter ≥ 2.5mm and bypass lesion 3. more than 3 stents required 4. patients refuse to be implanted stent 5. calcified lesion failed in pre-dilation, twisted lesion and lesion unsuitable for stent delivery and expansion 6. in-stent restenosis 7. planned percutaneous coronary intervention (pci) within 3 months post procedure 8. other stents implanted within 1 year 9. severe heart failure (nyha above iii) or left ventricle ejection fraction(ef) \<40% 10. renal function damage, blood creatinine \> 176.82 μmol/l 11. bleeding tendency, active peptic ulcer disease, cerebral or subarachnoid hemorrhage, cerebral apoplexy within half year and contraindication for any anti-platelet or anticoagulation agents 12. allergic to drugs or agents used in stent or protocol (plga, sirolimus, aspirin, clopidogrel, contrast agent, cobalt, nickel, chromium, iron, wolfram et. al.) 13. life expectation \< 12 months 14. have not reached the primary end point when participating in other trial 15. poor compliance to the protocol 16. heart implantation cases

Keywords: drug eluting stents interventional cardiology
low-load blood flow restriction on patients with multiple sclerosis

Conditions: Training Study; Multiple Sclerosis; Blood Flow Restriction

Summary: this research is being done to compare the current standard of care for strength training for patients with multiple sclerosis to lightweight resistance training with blood flow restriction.

the purpose of this study is to compare the effectiveness of the current multiple sclerosis standard of care exercise recommendations to low-load resistance training with blood flow restriction on functional outcomes, strength, muscle size, and neuromuscular control in multiple sclerosis patients. this study involves completing 2 training sessions per week for 12 weeks as well as pre- and post-training assessment visits for a total of 29 visits over 14 weeks. all visits will be on ucf's campus with a member of the research team.

Eligibility criteria:
inclusion criteria: * females between the ages of 18 to 55 * diagnosed with multiple sclerosis * expanded disability status score of 0 to 6.5 * able to walk 10 meters without assistance * are willing to come in for all 29 testing visits over 14 weeks exclusion criteria: * no other known cardiovascular, pulmonary, metabolic, muscular, and/or coronary heart disease * multiple sclerosis relapse in the past 30 days * are not currently undergoing a rehabilitation protocol * are not currently seeking medical care for a chronic condition that could limit exercise capacity other than multiple sclerosis * are not currently pregnant

Keywords: blood flow restriction multiple sclerosis exercise
positional stability and refractive behaviour after implantation of an iol after cataract surgery

Conditions: Ophthalmological Disorder

Summary: the newest generation lucia 621 has a step vault design that is claimed to provide excellent positional and refractive predictability. in order to explore the positional stability, anterior chamber depth stability is examined as marker for haptic buckling comparing positional behaviour after conventional and femtosecond-laser assisted cataract surgery.

in order to explore the positional stability, anterior chamber depth stability is examined as marker for haptic buckling comparing positional behaviour after conventional and femtosecond-laser assisted cataract surgery. furthermore, the refractive outcome of ct lucia 621p/py is examined, providing optimized (en bloc optimization) formula constants for both, conventional and femtosecond-laser assisted cataract surgery for haigis, hoffer q, holladay i, srk/t and castrop formulae. besides acd, further parameters for iol stability are examined (iol tilt/decentration) and consequences for the aberration profile are described.

Eligibility criteria:
inclusion criteria: * adult subject with a minimum age of 22 years * planned natural lens replacement with posterior chamber iol implantation * clear intraocular media other than cataract * availability, willingness, ability and sufficient cognitive awareness to comply with examination procedures and study visit * ability to consent to the participation in study * signed informed consent exclusion criteria: * corneal pathology/ectasia * prior ophthalmic surgery * zonular-defects, unstable bag * macular pathologies * expected visual acuity of less than 0.63 (decimal) * glaucoma * use of systemic or ocular medication that might affect vision * patient is pregnant, plans to become pregnant, is lactating * concurrent participation in any other clinical trial with an investigation product
the incidence of iv fluid over-administration in pediatric dental surgeries when infusion pumps are employed

Conditions: Dental Caries

Summary: a prospective, analyst-blinded, randomized control trial to assess the incidence of intravenous (iv) fluid over-administration in the setting of pediatric dental surgeries. anesthetists will be randomized to either administer their iv fluid through an infusion pump or a gravity drip device.

in the perioperative setting, iv fluids are administered to mitigate the effects of preoperative fasting and sources of fluid loss that are unique to surgical intervention. significant harms have been associated with the over-administration of iv fluid in pediatric patients. infusion pumps have been shown to reduce medication administration errors in inpatients receiving continuous iv infusions. in contrast, laboratory experiments have demonstrated that gravity driven fluid delivery systems are influenced by numerous extrinsic factors. to date, no work has investigated the perioperative incidence of iv fluid over-administration in pediatric patients randomized either to infusion pumps (intervention) or gravity-fed iv systems (control).

Eligibility criteria:
inclusion criteria: * asa 1 and 2 children presenting for dental surgery exclusion criteria: * children with pre-existing cardiac, renal, pulmonary or endocrine disease. in addition any child with an asa score of 3 or greater.

Keywords: pediatric perioperative intravenous fluid